These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Linaclotide: a novel compound for the treatment of irritable bowel syndrome with constipation.
    Author: Rothstein RD, Friedenberg FK.
    Journal: Expert Opin Pharmacother; 2013 Oct; 14(15):2125-32. PubMed ID: 24007408.
    Abstract:
    INTRODUCTION: Irritable Bowel Syndrome with constipation (IBS-C) is associated with abdominal pain and infrequent spontaneous bowel movements. Patients with Chronic Idiopathic Constipation do not have abdominal pain as a predominant symptom. Linaclotide represents a new class of medication approved in the USA for both of these common conditions. Linaclotide is approved for IBS-C only in the EU. The only other medication approved at this time for IBS-C is lubiprostone. AREAS COVERED: This review will cover the mechanism of action of linaclotide, and review the pivotal pre-clinical and clinical trials leading to its approval in 2012. The indications, common side effects, and black box warnings listed for linaclotide are reviewed. EXPERT OPINION: Linaclotide is superior to placebo for the treatment of both IBS-C and Chronic Idiopathic Constipation. The drug has minimal systemic bioavailability and a favorable safety profile. For IBS-C, it is appropriate as a first-line prescription treatment. For Chronic Idiopathic Constipation, osmotic or stimulant laxatives should be tried prior to using linaclotide due to their considerable lower cost.
    [Abstract] [Full Text] [Related] [New Search]